Kasumi-1
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
Kasumi-1 |
Humane Akute myelozytische Leukämie (AML) Zell-Linie |
300226 |
cryovial |
265,00 |
Kasumi-1 |
Humane Akute myelozytische Leukämie (AML) Zell-Linie |
330226 |
vital |
335,00 |
| Designation: | Kasumi-1 |
| Depositor: | Kamada |
| Organism: | Homo sapiens (human) |
| Ethnicity: | Japanese |
| Age/Stage: | 7 years |
| Gender: | male |
| Tissue: | Blood (acute myeloid leukemia=AML) |
| Morphology: | Round cells showing marked variations in both size and nuclear cytoplasmic ratio. |
| Celltype: | Myeloblast |
| Growth Properties: | suspension |
| Description: | The Kasumi-1 cell line was derived from the peripheral blood of a 7-year-old Japanese boy with AML (FAB M2) in relapse after bone marrow transplantation. Kasumi-1 cells have the characteristics of myeloid and macrophage lineages; they differentiate into macrophagelike cells when cultured with TPA. |
| Culture Medium: | RPMI 1640 medium supplemented with 2 mM L-glutamine and 20% fetal bovine serum. |
| Subculturing: | Start cultures at 3 x 105 cells/ml. Split the culture at a cell density of 6.0 to 8.0 x 105 cells/ml by transferring appropriate aliquots of the cell suspension to new flasks containing fresh cell culture medium. |
| Split Ratio: | A ratio of about 1:2 to 1:3 every 2 to 3 days is recommended. |
| Fluid Renewal: | Renew the medium by centrifuging and resuspending the cells in fresh medium |
| Doubling Time: | 40 to 45 hours |
| Freeze Medium: | CM-1 (CLS ∙ Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Karyotype: | t(8;21) chromosome translocation |
| DNA Profile (STR): | Amelogenin: X,X CSF1PO:10,12 D13S317:11,13 D16S539:9,12 D5S818:9,11 D7S820:8,11 TH01:6,9 TPOX:8,9 vWA:14 D3S1358: 15,17 D21S11: 30,31 D18S51: 15,16 Penta E: 11 Penta D: 12 D8S1179: 13,14 FGA: 22,24 |
| Immunology: | CD4+ (37.1%, coexpressed with CD34 and CD33), CD13+(OKM13), CD15+(LeuM1), CD33+, CD34+(MY10), CD38+(OKT10, 50.1%), CD71+(Nu-TERf), HLA-DR+(OKDR),. |
References: Asou H et al. Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation. Blood 77: 2031-6, 1991. Shimoda K et al. G-CSF induces tyrosine phosphorylation of the JAK2 protein in the human myeloid G-CSF responsive and proliferative cells, but not in the mature neutrophils. Biochemical and Biophysical Research Comminications 203: 922-8, 1994. Kwong YL et al. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21). Cancer 75: 821-5, 1995. Rhoades KL et al. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci USA 93: 11895-900, 1996. Miyoshi H et al. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with A T(8;21) chromosome translocation. Leuk Res 21: 45-50, 1997. Beghini A et al. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Exp Hematol 33: 682-8, 2005. Hiramatsu A et al. Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML. Leuk Lymphoma 47: 89-95, 2006. Lu Y et al. Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Leukemia 20: 987-93, 2006. Tamaki H et al. Antiapoptotic functionof 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 25: 4217-29, 2006. | |
